Pharmaceutical Executive
A decade into China’s far-reaching healthcare reforms-which began with the implementation of universal, albeit rudimentary, medical insurance-the pace of change and transformation within the country’s life sciences industry shows no signs of abating.
Let a Hundred Flowers Bloom
China's meteoric rise as an economic and political power on the global stage dominates discourse today. While the "Middle Kingdom" is reclaiming global attention, an equally remarkable story of transformation is coalescing within the country's healthcare and life sciences industry. A decade into China's far-reaching healthcare reforms, which began in 2009 with the implementation of universal, albeit rudimentary, medical insurance, the furious pace of change shows no signs of abating.
Since the State Council issued the Healthy China 2030 blueprint in October 2016, China has forged its own path toward the Holy Trinity of access, affordability, and innovation. A cascade of reforms and policies aimed at aligning China with the best practices of the global industry while accommodating the exceptional needs of the Chinese market is steadily shaping a new healthcare system with Chinese characteristics.
To view the full article on China's healthcare and life sciences markets, produced by Focus Reports and featured in Pharm Exec's September 2019 issue, click
here(cycle down to page 42).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.